Secarna strives to become the global partner of choice for all antisense oligonucleotide (ASO) drug discovery and development programs.

Our versatile business model is set to accommodate the best mix of in-house development and partner collaborations, addressing the core pillars of a successful partnership portfolio.

In-house Discovery & Development Pipeline: In-house initiation of new programs to discover and develop novel and/or promising ASOs as well as progress of selected high-value programs to predefined value inflection points. Secarna offers flexible partnering opportunities for further development and commercialization.

Discovery & Research Alliances: Single- or multiple-asset collaboration deals based on Secarna’s proprietary LNAplus antisense oligonucleotide discovery platform. The combination of Secarna’s know how and partner’s therapeutic expertise allows rapid generation of best-in-class, high-quality ASO pipelines, enabling cash-flow generation through tech access and license fees, milestone and royalty payments, and research funding. Overall placing the Company in an advantageous position, with an existing portfolio of partnered projects containing significant value.